CCRC Certification Exam — Questions and Answers

Question 1: Which of the following scenarios are considered SAEs?

boating accident with overnight hospitalization (Correct answer)
use of illicit drug during the trial
pregnancy resulting in normal delivery of twins
infection following surgery prolonging hospital stay (Correct answer)

Correct answer: boating accident with overnight hospitalization

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. An infection following surgery that prolongs a subject's hospital stay directly meets the criterion of 'prolongation of existing hospitalization,' thus qualifying as an SAE.

Question 2: Before a sponsor can legally ship an investigational new drug across state lines to a clinical investigator to begin a study in humans, the sponsor must first submit which application to the FDA?

A Biologics License Application (BLA)
A Marketing Authorization Application (MAA)
An Investigational New Drug (IND) application (Correct answer)
A New Drug Application (NDA)

Correct answer: An Investigational New Drug (IND) application

A sponsor must submit an Investigational New Drug (IND) application to the FDA before beginning any clinical research in humans. The IND provides data from preclinical studies to show that the product is reasonably safe for initial testing in humans. The sponsor must wait 30 days after IND submission before initiating trials, during which the FDA reviews the application for safety.

Question 3: According to U.S. federal regulations (21 CFR 312.6), which of the following statements is a mandatory element for the label of an investigational new drug?

The name of the Principal Investigator and the site number.
The date the protocol was approved by the Institutional Review Board (IRB).
"Caution: New Drug—Limited by Federal (or United States) law to investigational use." (Correct answer)
A full list of all potential adverse reactions listed in the Investigator's Brochure.

Correct answer: "Caution: New Drug—Limited by Federal (or United States) law to investigational use."

Federal regulation 21 CFR 312.6(a) explicitly mandates that the immediate package of an investigational new drug must bear the statement: "Caution: New Drug—Limited by Federal (or United States) law to investigational use." This is a critical regulatory requirement to clearly identify the product's status and restrict its use to the context of a clinical trial.

Question 4: What is a protocol deviation in the context of clinical research?

A formal modification to the protocol submitted by the sponsor
An adverse event directly caused by study procedures
A change to the protocol approved in advance by the IRB
Any unplanned departure from the procedures defined in the approved protocol (Correct answer)

Correct answer: Any unplanned departure from the procedures defined in the approved protocol

A protocol deviation is any unplanned departure from the approved procedures outlined in the study protocol.

Question 5: A research participant reports feeling nauseous after taking the investigational product. The CRC reviews the protocol and informed consent form, noting that nausea is a known and expected side effect. What is the CRC's most appropriate immediate next step?

Report the event to the IRB as an Unanticipated Problem within 24 hours.
Document the event, including its severity and duration, in the participant's source document.
Submit a Serious Adverse Event report to the sponsor. (Correct answer)
Instruct the participant to immediately discontinue the investigational product.

Correct answer: Submit a Serious Adverse Event report to the sponsor.

The CRC's immediate responsibility is to thoroughly document the clinical event in the source documentation. This includes details like onset, duration, severity, and any action taken. Since the event is expected and non-serious, it does not require immediate reporting to the IRB as an Unanticipated Problem or to the sponsor as an SAE. The decision to discontinue the product would be made by the Principal Investigator based on the event's severity and the protocol's guidance.

Question 6: Which of the following is the primary purpose of a Site Initiation Visit (SIV) conducted by the sponsor or a Contract Research Organization (CRO)?

To obtain informed consent from the first group of potential study participants.
To review and verify all participant data collected since the last monitoring visit.
To officially close out the study site and ensure all essential documents are properly archived.
To provide comprehensive, protocol-specific training to the site staff and verify readiness before the first participant is enrolled. (Correct answer)

Correct answer: To provide comprehensive, protocol-specific training to the site staff and verify readiness before the first participant is enrolled.

The Site Initiation Visit (SIV) occurs after regulatory approvals are in place but before participant enrollment begins. Its main purpose is to ensure the entire site team is thoroughly trained on the protocol, investigational product handling, data collection, and all trial-related duties to ensure the study is conducted correctly from the very start. It also serves to verify that the site has all necessary supplies and documentation to begin the trial.

Question 7: The FDA regulation 21 CFR Part 11 is a foundational component of modern clinical trial data management. What is its primary purpose?

To define the specific technical specifications for all Electronic Data Capture (EDC) software used in clinical trials.
To establish the standards under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records. (Correct answer)
To mandate the use of electronic systems for all new clinical trials to improve efficiency over paper-based methods.
To outline the security requirements for protecting patient privacy in electronic health records (EHRs), superseding HIPAA.

Correct answer: To establish the standards under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records.

21 CFR Part 11 provides the criteria for the FDA to accept electronic records and signatures as being as valid as their paper-based counterparts. It does not mandate specific software or the use of electronic systems, nor does it supersede HIPAA; rather, it ensures the integrity, authenticity, and confidentiality of electronic data submitted to the FDA.

Question 8: A protocol deviation rises to the level of a protocol violation when it:

Is reported to the sponsor after the study closes
Involves the investigational product in any way
Occurs more than once at the same site
Affects participant safety, rights, or data integrity (Correct answer)

Correct answer: Affects participant safety, rights, or data integrity

Deviations rise to the level of violations when they compromise participant safety, rights, welfare, or the integrity of collected data.

Question 9: Which regulatory form is used by a sponsor to report a serious unexpected adverse reaction to the FDA during an IND study?

IND Safety Report (15-day report) (Correct answer)
MedWatch Form FDA 3500A
Form FDA 1572
Form FDA 483

Correct answer: IND Safety Report (15-day report)

Sponsors must submit IND Safety Reports (expedited 15-day or 7-day reports) to the FDA for unexpected serious adverse reactions under 21 CFR 312.32.

Question 10: A sponsor asks the coordinator to change data in the EDC without a corresponding source document correction. What should the coordinator do?

Make the change as requested to keep the sponsor satisfied
Refuse and report the request to the PI and IRB as a potential GCP violation (Correct answer)
Ask the participant to sign a new consent form first
Make the change and note it as sponsor-directed

Correct answer: Refuse and report the request to the PI and IRB as a potential GCP violation

Altering data without source documentation is data falsification, a serious GCP violation; the coordinator must refuse and escalate to the PI and IRB.

Question 11: What is the average starting salary for a newly certified Clinical Research Coordinator?

$50,000 - $60,000
$40,000 - $50,000 (Correct answer)
$30,000 - $40,000
$60,000 - $70,000

Correct answer: $40,000 - $50,000

The average starting salary for a newly certified Clinical Research Coordinator typically falls within the range of $40,000 to $50,000. This figure can vary based on factors such as geographic location, the type of institution (e.g., academic, pharmaceutical company, CRO), and specific prior experience. However, this range represents a common entry-level compensation for individuals entering the field with certification.

Question 12: What is the primary and overarching responsibility of an Institutional Review Board (IRB)?

To protect the institution from legal and financial liability arising from research activities.
To protect the rights and welfare of human subjects participating in research. (Correct answer)
To facilitate the efficient and timely completion of clinical trials.
To ensure the scientific integrity and statistical power of the research design.

Correct answer: To protect the rights and welfare of human subjects participating in research.

The fundamental mission of the IRB, as mandated by federal regulations such as 45 CFR 46 and 21 CFR 56, is to ensure the protection of the rights and welfare of human research participants. While scientific merit is considered in the risk/benefit analysis, the IRB's primary role is ethical oversight and subject protection.

Question 13: During an informed consent discussion for a pediatric study, the CRC must obtain permission from the parents/legal guardian. What additional step is typically required for the pediatric participant?

Obtaining the child's assent using an age-appropriate form and discussion. (Correct answer)
Having the child sign the full informed consent form.
Documenting the child's verbal agreement in the source documents.
No additional step is needed if the parents provide consent.

Correct answer: Obtaining the child's assent using an age-appropriate form and discussion.

For research involving minors who have some capacity to understand, regulations and ethical guidelines require obtaining the child's affirmative agreement, known as assent, in addition to the permission of the parents or legally authorized representative. The assent process and form should be tailored to the child's age and developmental level.

Question 14: Which principle from the Belmont Report most directly supports the requirement for informed consent?

Justice
Respect for Persons (Correct answer)
Non-maleficence
Beneficence

Correct answer: Respect for Persons

Respect for Persons requires acknowledging individuals as autonomous agents capable of making their own decisions, which is operationalized through the informed consent process.

Question 15: A coordinator discovers that a colleague has been entering fabricated lab values into the study database. What is the appropriate response?

Correct the entries silently without reporting
Confront the colleague privately and ask them to stop
Ignore it to avoid workplace conflict
Report the concern to the PI, IRB, and institutional research integrity office (Correct answer)

Correct answer: Report the concern to the PI, IRB, and institutional research integrity office

Data fabrication is research misconduct; the coordinator has an ethical and regulatory obligation to report it to the PI, IRB, and the institution's research integrity office.

Question 16: After identifying a repeated pattern of the same protocol deviation at a site, the CRC and PI should FIRST:

Close the site immediately pending investigation
Remove all affected participants from the study
Conduct a root cause analysis and implement a CAPA (Corrective and Preventive Action) plan (Correct answer)
Notify the FDA directly without involving the sponsor

Correct answer: Conduct a root cause analysis and implement a CAPA (Corrective and Preventive Action) plan

A CAPA plan developed after root cause analysis is the standard quality improvement response to recurring deviations in clinical research.

Question 17: By signing the Form FDA 1572, a Principal Investigator (PI) makes a binding commitment to the FDA to perform which of the following actions?

Personally conduct every single study-related procedure for all enrolled participants.
Guarantee that a minimum number of participants will be enrolled at the site.
Ensure the investigation is conducted according to the current protocol and to personally supervise or conduct the investigation. (Correct answer)
Submit all study data directly to a peer-reviewed medical journal within six months of study completion.

Correct answer: Ensure the investigation is conducted according to the current protocol and to personally supervise or conduct the investigation.

The Form FDA 1572 is a legally binding agreement between the Principal Investigator and the FDA. By signing it, the PI commits to personally conduct or supervise the investigation, follow the current protocol, and ensure all regulatory requirements (including IRB review) are met to protect the rights, safety, and welfare of subjects. The form is a statement of commitment to regulatory and ethical conduct, not a guarantee of enrollment numbers or a publication plan.

Question 18: A study is designed to test a new antihypertensive drug. During the study, the investigators provide more frequent follow-up and encouragement to the participants in the active treatment group compared to the placebo group. This is an example of what type of bias?

Observer bias
Recall bias
Performance bias (Correct answer)
Selection bias

Correct answer: Performance bias

Performance bias occurs when there are systematic differences in the care provided to the comparison groups, other than the intervention being evaluated. In this scenario, the differential treatment of the groups (more attention to the active group) could influence the outcome independently of the drug's effect. Blinding of investigators and participants is the primary method to prevent this type of bias.

Question 19: Which of the following is a mandatory membership requirement for an Institutional Review Board (IRB) as specified by federal regulations (45 CFR 46)?

All members of the IRB must be employees of the institution to ensure accountability.
The IRB chairperson must be a physician with clinical research experience.
The IRB must include at least two members with doctoral degrees in a biomedical science.
The IRB must have at least one member who is not affiliated with the institution. (Correct answer)

Correct answer: The IRB must have at least one member who is not affiliated with the institution.

Federal regulations (45 CFR 46.107) require that each IRB include at least one member who is not otherwise affiliated with the institution (and is not an immediate family member of an affiliated person). This is to ensure that the IRB review includes a community or public perspective, independent of the institution.

Question 20: An FDA investigator arrives unannounced for a study inspection. What is the first step the coordinator should take?

Ask the investigator to return with a scheduled appointment
Notify the principal investigator and sponsor immediately (Correct answer)
Begin shredding outdated study documents
Delay the inspection until legal counsel is present

Correct answer: Notify the principal investigator and sponsor immediately

The site must welcome the FDA inspector and promptly notify the PI and sponsor so the appropriate personnel and documents are made available.

Question 21: What is the purpose of a Corrective and Preventive Action (CAPA) plan submitted to a sponsor after a monitoring finding?

To request additional study budget
To notify the FDA of site non-compliance
To document and resolve protocol deviations and prevent recurrence (Correct answer)
To terminate the site's participation in the trial

Correct answer: To document and resolve protocol deviations and prevent recurrence

A CAPA plan identifies the root cause of a finding and details specific steps to correct the problem and prevent it from happening again.

Question 22: What is the FIRST action a CRC should take upon identifying a protocol deviation?

Terminate the affected participant from the study
Document the deviation and notify the principal investigator (Correct answer)
Immediately notify the FDA
Submit a protocol amendment to the IRB

Correct answer: Document the deviation and notify the principal investigator

The first step is to document the deviation thoroughly and notify the PI, who is ultimately responsible for protocol compliance at the site.

Question 23: A subject is participating in a clinical trial where only the pharmacist and the sponsor know the identity of the IP. The pharmacist has no direct contact with the trial subject and the clinical team. Which of the following BEST describes this trial type?

double-blind (Correct answer)
single-blind
Triple-blind

Correct answer: double-blind

Phase 1 clinical trials are the initial human studies for a new drug, primarily focused on safety and basic pharmacological properties. 'Dose escalation' is a key component, gradually increasing the dose to find a safe and tolerable range. 'Pharmacokinetic analysis' is also crucial, as it studies how the drug is absorbed, distributed, metabolized, and excreted in the body, providing essential information for subsequent trial phases.

Question 24: A monitor is conducting source data verification (SDV) and notes that a blood pressure reading of '130/85' recorded in the electronic Case Report Form (eCRF) does not match the value of '135/80' written in the participant's original, signed progress note. This discrepancy is a violation of which core ALCOA-C principle of good documentation practice?

Legible
Contemporaneous
Attributable
Accurate (Correct answer)

Correct answer: Accurate

The principle of "Accurate" documentation requires that the data recorded is a correct reflection of the source information. In this case, the discrepancy between the eCRF and the source document (the progress note) means the transcribed data in the eCRF is not accurate. The other principles, while important, do not directly address the correctness of the transcribed data.

Question 25: When must a US investigational site submit a progress report to the IRB?

At least annually, or more frequently if required by the IRB (Correct answer)
Only at the end of the study
Only when a serious adverse event occurs
Every six months regardless of IRB requirements

Correct answer: At least annually, or more frequently if required by the IRB

Under 21 CFR 56.108, sites must submit continuing review reports to the IRB at least annually to maintain approval for ongoing studies.

Question 26: A study participant is scheduled for their Week 4 visit, which has a protocol-specified visit window of +/- 3 days. The participant calls with a personal emergency and is unable to come to the clinic until 7 days after the target date, which is outside the visit window. How should the CRC classify and handle this occurrence?

As a protocol deviation that must be documented and reported according to site and sponsor procedures. (Correct answer)
As a minor issue that does not require documentation since the participant eventually completed the visit.
As a critical protocol violation that requires the participant to be immediately withdrawn from the study.
As a serious adverse event (SAE) requiring immediate reporting.

Correct answer: As a protocol deviation that must be documented and reported according to site and sponsor procedures.

A protocol deviation is any unplanned excursion from the procedures defined in the IRB-approved protocol. A visit occurring outside the specified window is a common example of a deviation. This event must be documented in the source records and reported to the sponsor and/or IRB according to the protocol and institutional policies. It is not an adverse event, and while it's a deviation, it doesn't typically warrant immediate withdrawal unless it is part of a pattern of non-adherence or significantly impacts safety or data integrity.

Question 27: What is the purpose of a Delegation of Authority (DoA) log in a clinical trial?

To list all protocol amendments approved during the study
To track adverse event reports sent to the IRB
To record which tasks have been assigned to qualified staff by the PI (Correct answer)
To document sponsor payments to the site

Correct answer: To record which tasks have been assigned to qualified staff by the PI

The DoA log documents that the PI has formally assigned specific trial tasks to qualified, trained staff members and is a key GCP requirement.

Question 28: During the conduct of a trial, the Principal Investigator realizes that a participant's screening lab tests were inadvertently performed one day before the informed consent form was signed and dated. How should the CRC expect this event to be handled with respect to the IRB?

The event must be reported to the IRB as a protocol deviation, as study procedures were conducted prior to obtaining consent. (Correct answer)
The PI should inform the sponsor but wait for sponsor direction before taking any action with the IRB.
The event should be documented in the site's internal files but does not need to be reported to the IRB as long as the participant was ultimately eligible.
The participant should be asked to re-consent and back-date the form to the day before the lab draw to correct the error.

Correct answer: The event must be reported to the IRB as a protocol deviation, as study procedures were conducted prior to obtaining consent.

Conducting any study-related procedure before obtaining and documenting informed consent is a significant protocol deviation and a violation of fundamental ethical principles and regulations. The site has an obligation to report such deviations to the IRB according to institutional policy, which is typically within a specified timeframe (e.g., 5-10 business days) of discovery.

Question 29: A CRC measures a participant's blood pressure and immediately records the value, along with the time, date, and their initials, on the designated paper source worksheet. This practice best exemplifies which principle of ALCOA-C?

Contemporaneous (Correct answer)
Accurate
Attributable
Legible

Correct answer: Contemporaneous

The principle of 'Contemporaneous' requires that data be recorded at the time it is generated or observed. By documenting the blood pressure reading immediately after taking it, the CRC ensures the record reflects the real-time event, preventing errors from recall. While the initials make it 'Attributable' and the value should be 'Accurate', the act of recording it *immediately* is the key to it being 'Contemporaneous'.

Question 30: Which of the following statements is most accurate regarding the Investigator's Brochure (IB)?

It is a comprehensive compilation of the clinical and nonclinical data on the investigational product known to date and is maintained by the sponsor. (Correct answer)
It is a promotional document designed to highlight the potential benefits of the investigational product to recruit investigators.
It contains only the protocol and informed consent form for a specific clinical trial.
It is created by the clinical research coordinator and is only updated upon completion of the study for the final report to the IRB.

Correct answer: It is a comprehensive compilation of the clinical and nonclinical data on the investigational product known to date and is maintained by the sponsor.

According to ICH GCP guidelines, the Investigator's Brochure (IB) is a comprehensive document that summarizes the body of information known about an investigational product, including nonclinical and clinical data. The sponsor is responsible for creating it and keeping it up to date, with a review at least annually. The information must be presented in an objective, non-promotional manner.

Question 31: At the conclusion of a clinical trial, after all data has been entered, cleaned, and all queries resolved, the sponsor performs a "database lock." What is the primary significance of this action?

It automatically submits the final clinical study report to the regulatory authorities.
It archives the study data, but allows the CRC to continue making corrections as needed.
It triggers the final payment from the sponsor to the research site.
It prevents any further changes to the data, creating a static dataset for final statistical analysis. (Correct answer)

Correct answer: It prevents any further changes to the data, creating a static dataset for final statistical analysis.

A database lock is a critical milestone that marks the transition from data collection and cleaning to data analysis. Once the database is locked, no further alterations to the data are permitted, which ensures the integrity and reproducibility of the final analysis that will be used for the clinical study report and regulatory submissions.

Question 32: What is the primary ethical concern when enrolling patients who have a dependent relationship with the investigator (e.g., the PI's own patients)?

Potential undue influence that may compromise voluntary participation (Correct answer)
Violation of HIPAA authorization requirements
Increased cost of the clinical trial
Lack of scientific validity of enrolled data

Correct answer: Potential undue influence that may compromise voluntary participation

A dependent relationship between investigator and participant creates a risk of undue influence, where patients may feel obligated to enroll or unable to withdraw without jeopardizing their care.

Question 33: A PI submits a protocol for a new minimal-risk study that will involve a one-time blood draw and a quality-of-life survey for healthy adults. This type of research typically does not require review at a convened IRB meeting. This level of review is known as:

Exempt Determination
Delayed Review
Expedited Review (Correct answer)
Full Board Review

Correct answer: Expedited Review

Research activities that involve no more than minimal risk to subjects and fall into one of the specific categories defined by federal regulations can be reviewed through an expedited process. This review is carried out by the IRB chairperson or by one or more experienced reviewers designated by the chairperson, not by the full committee. An exempt determination is for research with even lower or no apparent risk, while full board review is for studies with greater than minimal risk.

Question 34: A participant received a study drug dose 20% higher than specified in the protocol due to a calculation error. This event is BEST classified as:

An expected drug reaction to be noted in the participant's medical record
A serious adverse event requiring expedited safety reporting only
A protocol deviation requiring documentation and reporting to the sponsor (Correct answer)
A minor administrative error requiring no formal action

Correct answer: A protocol deviation requiring documentation and reporting to the sponsor

An incorrect dosing error is a protocol deviation (and likely a major one) that must be documented and reported to the sponsor and potentially the IRB.

Question 35: A coordinator is aware that the PI has not reported a protocol deviation to the IRB as required. What should the coordinator do?

Report the deviation to the IRB directly without informing the PI
Notify the sponsor and close the study
Do nothing, as reporting is solely the PI's responsibility
Remind the PI of the reporting obligation and document the interaction (Correct answer)

Correct answer: Remind the PI of the reporting obligation and document the interaction

The coordinator should remind the PI of the mandatory reporting requirement and document the conversation; if the PI still fails to report, escalation through institutional channels is appropriate.

Question 36: During a Phase III trial, a participant experiences an allergic reaction resulting in anaphylactic shock, which requires emergency intervention and hospitalization. This specific type of reaction was not previously identified in the Investigator's Brochure. This event should be categorized as a:

Non-serious Adverse Drug Reaction (ADR).
Protocol Violation.
Serious Adverse Event (SAE) only.
Suspected Unexpected Serious Adverse Reaction (SUSAR). (Correct answer)

Correct answer: Suspected Unexpected Serious Adverse Reaction (SUSAR).

This event is a SUSAR because it meets all three criteria: It is Serious (life-threatening, requires hospitalization), Unexpected (not listed in the Investigator's Brochure), and a suspected Adverse Reaction (a causal relationship is suspected). While it is an SAE, the more specific and complete classification is SUSAR, which triggers expedited reporting to regulatory authorities by the sponsor.

Question 37: Which of the following information must be included in a deviation report submitted to the sponsor?

Financial compensation records for all site staff involved
Only the date and the affected participant's ID number
A complete list of all participants currently enrolled in the study
Description of the deviation, date, impact on safety and data, and corrective/preventive actions taken (Correct answer)

Correct answer: Description of the deviation, date, impact on safety and data, and corrective/preventive actions taken

A complete deviation report includes the nature of the deviation, when it occurred, its impact on safety and data integrity, and the corrective and preventive actions taken.

Question 38: A protocol amendment that changes the primary study endpoint requires:

Only sponsor notification without IRB review
IRB review and approval before implementation at the site (Correct answer)
Only a notation added to the site's study file
Immediate implementation followed by retroactive IRB review

Correct answer: IRB review and approval before implementation at the site

Changes to primary endpoints are substantive amendments that require IRB review and approval before the site can implement them.

Question 39: A participant has been enrolled in a long-term oncology trial for two years. The sponsor issues a protocol amendment that introduces a new, optional sub-study involving additional blood draws to test for a novel biomarker. What is the CRC's responsibility regarding the informed consent for this change?

Ensure the participant is re-consented using a new, IRB-approved consent form that details the optional sub-study. (Correct answer)
Obtain verbal consent from the participant for the sub-study and document it in the progress notes.
No action is needed as the main study consent covers minor additions.
Inform the participant of the new sub-study during their next visit without requiring a signature.

Correct answer: Ensure the participant is re-consented using a new, IRB-approved consent form that details the optional sub-study.

Significant new information, such as additional procedures or changes in risk, requires that participants be re-consented. The CRC must use a revised, IRB-approved informed consent form to explain the changes and document the participant's willingness to continue in the trial under the new conditions.

Question 40: By signing the FDA Form 1572, Statement of Investigator, a clinical investigator makes a binding commitment to the sponsor to perform which of the following actions?

Submit the final study report and New Drug Application directly to the FDA.
Personally conduct or supervise the investigation and ensure that all study staff are informed about their obligations. (Correct answer)
Guarantee a minimum number of participants will be enrolled at the site.
Publish the study results in a peer-reviewed journal within one year of study completion.

Correct answer: Personally conduct or supervise the investigation and ensure that all study staff are informed about their obligations.

The FDA Form 1572 is a legally binding agreement between the investigator and the sponsor. By signing it, the investigator commits to personally conduct or supervise the study, follow the protocol, comply with all applicable regulations (including obtaining informed consent and IRB review), and ensure all assisting staff are properly informed of their duties.

Question 41: Which of the following is an example of a MINOR protocol deviation?

Failure to obtain informed consent before conducting study procedures
Administration of a prohibited concomitant medication throughout the study
A study visit completed one day outside the allowed window with no impact on data quality (Correct answer)
Enrollment of a participant who failed a key exclusion criterion

Correct answer: A study visit completed one day outside the allowed window with no impact on data quality

A visit completed one day outside the window with no impact on participant safety or data integrity is typically classified as a minor deviation.

Question 42: A potential participant in a clinical trial is fully fluent in Spanish but has limited English proficiency. The IRB-approved informed consent form (ICF) is only available in English. Which of the following is the most appropriate action for the Clinical Research Coordinator (CRC) to take?

Use a qualified, impartial interpreter to translate the English ICF to the participant during the consent discussion and document the process thoroughly.
Provide the participant with the English ICF and ask them to use a consumer translation app on their phone for understanding.
Inform the participant they cannot be enrolled until an official, IRB-approved Spanish translation of the ICF is available. (Correct answer)
Proceed with the consent process using the English ICF and have a bilingual site staff member informally translate key sections.

Correct answer: Inform the participant they cannot be enrolled until an official, IRB-approved Spanish translation of the ICF is available.

According to ICH GCP and FDA regulations, the informed consent information must be provided in a language understandable to the subject. Using an unapproved, on-the-spot translation does not meet regulatory standards. The correct and ethical procedure is to use an IRB-approved translated consent form to ensure the participant fully understands the study, its risks, and their rights before providing consent.

Question 43: A CRC discovers that a protocol deviation occurred 2 weeks ago but was never documented. The BEST course of action is to:

Ignore it since sufficient time has passed and it may not be found
Document the deviation now with a note explaining the delay and notify the PI (Correct answer)
Terminate the affected participant immediately from the study
Destroy any evidence to prevent an audit finding

Correct answer: Document the deviation now with a note explaining the delay and notify the PI

Late documentation is always better than no documentation; the CRC should document the deviation with an explanation of the delay and escalate appropriately to the PI.

Question 44: During a monitoring visit, the monitor needs to perform source data verification (SDV) for a participant's concomitant medications listed in the eCRF. Which of the following would be considered the most reliable primary source document for this information?

The participant's self-reported medication log provided at the beginning of the study.
The participant's official electronic health record (EHR) or signed progress notes from their medical file. (Correct answer)
The electronic Case Report Form (eCRF) page where the medications are listed.
The study's Investigational Product accountability log.

Correct answer: The participant's official electronic health record (EHR) or signed progress notes from their medical file.

Source data is the original record of clinical findings, observations, or other activities. The participant's official medical record (EHR or paper chart) is the most reliable source because it is a part of their routine clinical care. The eCRF is a transcription of the source, a self-reported log is subject to recall bias, and the IP accountability log only tracks the study drug.

Question 45: What does the ethical principle of beneficence require of clinical researchers?

Respecting participants' right to withdraw at any time
Maximizing potential benefits and minimizing potential harms to participants (Correct answer)
Treating all participants equitably regardless of background
Disclosing all financial conflicts of interest

Correct answer: Maximizing potential benefits and minimizing potential harms to participants

Beneficence obligates researchers to actively protect participant welfare by maximizing benefits and minimizing risks — going beyond simply doing no harm.

Question 46: An investigator delegates the task of obtaining informed consent to the CRC. The consent form is signed and dated by the participant and the CRC. Later, a monitor reviewing the study files notes an error. Which of the following represents a common and significant documentation error in the informed consent process?

The version of the consent form used was outdated and had been superseded by a more recent IRB-approved version. (Correct answer)
The consent discussion took place in a private examination room.
The participant was given a copy of the signed consent form to take home.
The CRC who obtained consent was listed on the delegation of authority log for that task.

Correct answer: The version of the consent form used was outdated and had been superseded by a more recent IRB-approved version.

Using an outdated or incorrect version of the informed consent form is a serious regulatory violation and a common finding in audits and inspections. The CRC is responsible for ensuring that only the most current, IRB-approved version of the ICF is used for every participant enrollment.

Question 47: What does Form FDA 1572 (Statement of Investigator) legally commit the principal investigator to?

Certifying that all study staff hold medical licenses
Agreeing to conduct the study according to the protocol and applicable regulations (Correct answer)
Submitting annual reports directly to the FDA
Approving the study budget on behalf of the institution

Correct answer: Agreeing to conduct the study according to the protocol and applicable regulations

By signing Form FDA 1572, the investigator commits to conducting the trial per the protocol, GCP, and relevant FDA regulations including recordkeeping and reporting obligations.

Question 48: A CRC is transcribing a participant's weight from a source document into the Electronic Data Capture (EDC) system. The source clearly states the weight is 90.5 kg. When the CRC enters "90.5" into the weight field, an automated edit check fires a query stating, "Value is outside the expected range of 100-250. Please confirm." The CRC realizes the EDC was mistakenly programmed to expect the value in pounds (lbs). What is the most appropriate action?

Leave the field blank and make a note in the participant's paper chart about the system error.
Ask the clinical trial manager to grant a one-time system override to accept the value of 90.5 without a query.
Do not change the data; respond to the query stating that the value of 90.5 kg is correct per the source document and that the edit check requires review. (Correct answer)
Convert 90.5 kg to pounds (approx. 199.5 lbs) and enter "199.5" into the field to resolve the query.

Correct answer: Do not change the data; respond to the query stating that the value of 90.5 kg is correct per the source document and that the edit check requires review.

The fundamental rule of data entry is that the data in the Case Report Form (CRF) must accurately reflect the source document. Changing the value to fit the incorrect edit check constitutes data manipulation. The correct action is to enter the accurate data from the source, and use the query system to communicate the discrepancy and flag the system programming error to the data management team.

Question 49: What is the ethical rationale for including women and minorities as required participants in federally funded clinical research in the US?

To satisfy NIH Revitalization Act requirements ensuring results are generalizable across populations (Correct answer)
To increase enrollment speed
To comply with HIPAA data diversity requirements
To reduce the cost of the study

Correct answer: To satisfy NIH Revitalization Act requirements ensuring results are generalizable across populations

The NIH Revitalization Act of 1993 mandates inclusion of women and minorities in federally funded research so that findings are applicable to all segments of the US population.

Question 50: Which federal regulation requires financial conflict of interest disclosure for PHS-funded research at US institutions?

21 CFR Part 50
42 CFR Part 50 / 45 CFR Part 94 (Correct answer)
45 CFR Part 46
21 CFR Part 312

Correct answer: 42 CFR Part 50 / 45 CFR Part 94

42 CFR Part 50 and 45 CFR Part 94 govern financial conflict of interest reporting requirements for investigators on PHS (NIH) funded research.

Question 51: When must a protocol amendment be submitted to the IRB for review and approval?

Only when the amendment changes the primary endpoint
Before implementing any change to the approved protocol (Correct answer)
Within 30 days after implementing the change
Only when the sponsor formally requests IRB review

Correct answer: Before implementing any change to the approved protocol

Per ICH GCP E6(R2), any amendments to the protocol must be submitted to the IRB and approved before implementation, unless an immediate safety deviation is required.

Question 52: A CRC receives an automated query in the EDC system because a participant, enrolled under an inclusion criterion of "age 18-75," has a calculated age of 76. The CRC verifies against the participant's driver's license (the source document) that the date of birth was entered correctly and the participant was, in fact, ineligible. What is the CRC's most appropriate action?

Ignore the query, as the Principal Investigator is ultimately responsible for all participant eligibility.
Change the date of birth in the EDC by one year to resolve the query and make the participant eligible.
Respond to the query confirming the data is accurate per the source, and immediately report the enrollment of an ineligible participant as a protocol deviation. (Correct answer)
Delete the participant's record from the EDC system since they were never truly eligible for the study.

Correct answer: Respond to the query confirming the data is accurate per the source, and immediately report the enrollment of an ineligible participant as a protocol deviation.

Data integrity requires that the information in the EDC accurately reflects the source. The correct action is to confirm the data's accuracy in the query response. Concurrently, the enrollment of an ineligible participant is a protocol deviation that must be documented and reported immediately to the PI and, subsequently, the IRB/sponsor according to the site's SOPs.

Question 53: Which of the following documents is essential to have completed, signed, and filed in the site's regulatory binder BEFORE a clinical trial can be initiated at the site?

A log of all participants who have successfully completed the study.
A signed and dated FDA Form 1572. (Correct answer)
A record of all Serious Adverse Event reports submitted to the sponsor.
The final, signed clinical study report.

Correct answer: A signed and dated FDA Form 1572.

The FDA Form 1572, or Statement of Investigator, is a legally binding agreement between the investigator and the FDA. By signing it, the investigator commits to conducting the study in accordance with federal regulations. This form, along with IRB approval and the protocol signature page, is a foundational document that must be in place before any study activities, including participant recruitment, can begin.

Question 54: Which of the following best describes a 'close-out visit' conducted by a sponsor?

A visit to conduct a final IRB inspection
A visit to enroll the last participant
A visit to announce study results to site staff
A visit to reconcile drug supplies, archive documents, and verify study completion (Correct answer)

Correct answer: A visit to reconcile drug supplies, archive documents, and verify study completion

During a close-out visit, the sponsor's CRA reconciles investigational product, ensures all data queries are resolved, and confirms the site's documentation is ready for archiving.

Question 55: Which document outlines the sponsor's expectations for site conduct and is the primary agreement between a sponsor and a clinical investigator?

Investigator Agreement
Delegation of Authority Log
Protocol
Clinical Trial Agreement (Correct answer)

Correct answer: Clinical Trial Agreement

The Clinical Trial Agreement (CTA) is the binding contract between the sponsor and the site that governs financial, operational, and legal obligations.

Question 56: A Clinical Research Coordinator (CRC) at a busy site discovers that a blood sample required for a key secondary endpoint, scheduled for the Week 4 visit, was missed for a participant who has already left the clinic. The protocol's visit window for this draw has now passed. How should the CRC best manage and document this situation?

Wait until the next scheduled visit to draw the sample and label it as the Week 4 sample to complete the case report form.
Document the event as a protocol deviation and report it to the investigator and, if required, the sponsor/CRO. (Correct answer)
Ignore the missed sample since it is for a secondary, not primary, endpoint.
Ask the participant to return immediately, even though it is outside the protocol-defined window, to ensure the data is collected.

Correct answer: Document the event as a protocol deviation and report it to the investigator and, if required, the sponsor/CRO.

According to Good Clinical Practice (GCP), any departure from the protocol-approved procedures constitutes a protocol deviation. It must be documented accurately and reported to ensure data integrity and participant safety are not compromised. Attempting to collect the sample outside the window or mislabeling a future sample would be falsification of data. Ignoring the issue, even for a secondary endpoint, is inappropriate and compromises the quality of the study data.

Question 57: Which of the following is the primary purpose of randomization in a clinical trial?

To prevent selection bias by creating comparable study groups. (Correct answer)
To ensure that all participants receive the investigational product.
To guarantee that the study results will be statistically significant.
To make it easier to recruit participants for the study.

Correct answer: To prevent selection bias by creating comparable study groups.

The primary purpose of randomization is to minimize selection bias by ensuring that each participant has an equal chance of being assigned to any of the treatment groups. This process helps to create groups that are comparable in terms of both known and unknown prognostic factors, so that any observed differences in outcomes can be attributed to the intervention being studied rather than pre-existing differences between the groups.

Question 58: During a Phase I trial for a new antiviral agent, several participants are hospitalized with acute liver failure, an unexpected and severe adverse reaction. The FDA orders the sponsor to immediately stop dosing all participants and halt new enrollment. This regulatory action is called a:

Protocol Deviation Report
Sponsor-Initiated Suspension
IRB Revocation of Approval
Clinical Hold (Correct answer)

Correct answer: Clinical Hold

A clinical hold is an order issued by the FDA to a sponsor to delay a proposed clinical investigation or to suspend an ongoing one. This action is taken if, among other reasons, human subjects are or would be exposed to an unreasonable and significant risk of illness or injury.

Question 59: What is the expected job growth for Clinical Research Coordinators over the next decade?

Grow by 20% (Correct answer)
No significant change
Decline by 5%
Grow by 10%

Correct answer: Grow by 20%

The job outlook for Clinical Research Coordinators (CRCs) is projected to grow significantly over the next decade, with an estimated growth rate of 20%. This robust growth is driven by the increasing demand for new medical treatments and technologies, an aging global population, and the growing complexity of clinical trials. This indicates a much faster than average growth for this profession.

Question 60: Under which circumstance may a site implement a protocol change BEFORE receiving formal IRB approval?

When the sponsor requests immediate implementation in writing
When the change is purely administrative in nature and does not affect procedures
When the PI deems it clinically appropriate for a specific participant
When the change is needed to eliminate an immediate hazard to participants (Correct answer)

Correct answer: When the change is needed to eliminate an immediate hazard to participants

ICH GCP E6(R2) Section 4.5.2 permits immediate implementation of changes needed to eliminate immediate hazards to participants, with retroactive IRB reporting.

Question 61: Which of the following elements is essential for a compliant Investigational Product (IP) accountability record at a clinical trial site?

The name and signature of the monitor who last reviewed the records.
Lot number, expiration date, and quantities received, dispensed, and returned. (Correct answer)
The participant's full name and medical record number for each dispensing event.
The manufacturing cost and batch release date of the investigational product.

Correct answer: Lot number, expiration date, and quantities received, dispensed, and returned.

ICH GCP guidelines require meticulous tracking of the IP to ensure it's only used for study participants as per the protocol. The accountability record, or drug accountability log, must track the lifecycle of the IP at the site, which includes unique identifiers like lot/batch numbers and expiration dates, as well as a running inventory of units received from the sponsor, dispensed to each participant (identified by a unique subject ID), and returned or otherwise disposed of.

Question 62: A CRC receives a shipment of investigational product. Upon inspection, the CRC notes that the external shipping container is intact, but the seal on one of the primary drug bottles inside is broken. What is the most appropriate action?

Discard the bottle immediately in the pharmaceutical waste and only document the receipt of the intact bottles to avoid confusion.
Segregate the bottle with the broken seal, quarantine it, document the issue thoroughly, and contact the sponsor/depot for instructions. (Correct answer)
Use the product from the bottle since the outer container was sealed, assuming it was a minor manufacturing defect.
Document the broken seal on the shipping receipt and store the affected bottle with the general IP inventory.

Correct answer: Segregate the bottle with the broken seal, quarantine it, document the issue thoroughly, and contact the sponsor/depot for instructions.

The integrity of the investigational product is paramount to patient safety and data validity. A broken seal compromises the product's integrity. The correct procedure is to immediately isolate the affected product to prevent it from being dispensed, document the deviation clearly on all records, and quarantine it while contacting the sponsor or designated pharmacy/depot for guidance on how to handle the compromised unit (e.g., return or destruction).

Question 63: The sponsor of a global oncology trial issues a protocol amendment. The only change is the addition of a new, non-investigational laboratory test to be drawn at the Week 8 visit to monitor for a rare but known side effect. What must the CRC confirm before implementing this change for any participants?

That the Principal Investigator has personally signed off on the scientific merit of the change.
That the protocol amendment and any revised consent forms have been submitted to and approved by the IRB. (Correct answer)
That the site's lab is certified to perform the new test.
That the sponsor has notified the FDA of the change.

Correct answer: That the protocol amendment and any revised consent forms have been submitted to and approved by the IRB.

Investigators are prohibited from implementing any changes to a previously approved research plan without first obtaining IRB review and approval. The only exception is when a change is necessary to eliminate an apparent immediate hazard to subjects. Even seemingly minor changes like adding a safety lab test require formal IRB approval of the amendment before they can be implemented.

Question 64: A clinical trial is designed where neither the participants nor the investigators interacting with them know who is receiving the experimental drug and who is receiving the placebo. This type of study is best described as:

A double-blind study (Correct answer)
An open-label study
A crossover study
A single-blind study

Correct answer: A double-blind study

A double-blind study is a design in which neither the participants nor the investigators (including study staff who interact with participants) are aware of the treatment allocation. This method is crucial for minimizing bias, as knowledge of the treatment could influence participant reporting, staff administration of the intervention, or outcome assessment.

Question 65: A research coordinator is working on a study that investigates the association between a specific dietary habit (exposure) and the development of a rare disease. The study identifies individuals who already have the disease (cases) and a similar group without the disease (controls), and then looks back in time to compare their past dietary habits. What is this type of observational study design called?

Cross-sectional study
Case-control study (Correct answer)
Prospective cohort study
Randomized controlled trial

Correct answer: Case-control study

This scenario describes a case-control study. This is a retrospective observational design where the researcher begins with the outcome (the presence or absence of the disease) and then looks backward to ascertain differences in exposure between the two groups. It is particularly useful for studying rare diseases or outcomes with long latency periods.

Question 66: Under FDA regulations (21 CFR 312.62), how long must clinical trial records generally be retained after the study is completed?

Until the principal investigator retires from practice
5 years from study completion
At least 2 years after the investigational product's marketing application is approved or investigations discontinued (Correct answer)
2 years from study completion

Correct answer: At least 2 years after the investigational product's marketing application is approved or investigations discontinued

FDA regulations require that records be retained for at least 2 years after a marketing application is approved or clinical investigations are discontinued.

Question 67: What is the coordinator's role when a sponsor requests a protocol deviation waiver for a specific participant?

Allow the deviation only if the sponsor provides written authorization
Approve the waiver independently and document it
Deny the waiver to maintain protocol integrity
Facilitate IRB notification or approval as required and document the deviation (Correct answer)

Correct answer: Facilitate IRB notification or approval as required and document the deviation

Protocol deviations must be documented, reported to the IRB per its requirements, and communicated to the sponsor regardless of whether a waiver is sought.

Question 68: Which of the following is an example of a MAJOR protocol deviation?

A minor typographical error in a study log entry
Enrollment of a participant who did not meet all inclusion criteria (Correct answer)
A study visit conducted one day outside the allowed window with no data impact
A participant completing a questionnaire in a different room than specified

Correct answer: Enrollment of a participant who did not meet all inclusion criteria

Enrolling a participant who does not meet eligibility criteria is a major deviation because it may affect data integrity and participant safety.

Question 69: When is a waiver of informed consent permissible for non-exempt research under the US Common Rule (45 CFR 46)?

Whenever the sponsor requests it for operational convenience
When the research involves no more than minimal risk, cannot practicably be carried out without the waiver, and rights are not adversely affected (Correct answer)
When the study involves only retrospective chart review regardless of risk
When participants are unable to read the consent form

Correct answer: When the research involves no more than minimal risk, cannot practicably be carried out without the waiver, and rights are not adversely affected

Under 45 CFR 46.116(f), a waiver of consent may be granted if the research poses no more than minimal risk, cannot practicably be conducted otherwise, and does not adversely affect participant rights.

Question 70: Which of the following is a primary responsibility of the Clinical Research Coordinator (CRC) in the management of adverse events?

Ensuring accurate and timely documentation of the event in the source documents and Case Report Forms (CRFs). (Correct answer)
Modifying the protocol to mitigate future risks.
Informing the FDA directly of all Serious Adverse Events.
Determining the final causality assessment of the event.

Correct answer: Ensuring accurate and timely documentation of the event in the source documents and Case Report Forms (CRFs).

The CRC plays a critical role in ensuring that all adverse events are accurately and promptly documented in the participant's source records and transcribed correctly onto the CRFs. While the CRC assists in collecting information, the Principal Investigator is ultimately responsible for the causality assessment. The sponsor, not the site CRC, is responsible for reporting SAEs to the FDA. Protocol modifications are the responsibility of the sponsor.

Question 71: A CRC is screening subjects for an oral IP. All subjects must be stabilized on currently approved medications. Which of the following questions should be asked by the CRC?

When was the last time your medication dose changed? (Correct answer)
Have you made any dietary changes in the last month?
When was your last chest x-ray and ECG?
Do you have any difficulty swallowing oral medications? (Correct answer)

Correct answer: When was the last time your medication dose changed?

When screening subjects for a clinical trial requiring stabilization on currently approved medications, it is critical to ascertain the stability of their current treatment regimen. Asking 'When was the last time your medication dose changed?' directly addresses whether their existing medications are stable and have not recently been adjusted. This ensures that any observed effects during the trial are more likely attributable to the investigational product and not to recent changes in concomitant medications.

Question 72: Under HIPAA, what is the minimum necessary standard as applied to clinical research?

Protected health information should be limited to the minimum needed to accomplish the research purpose (Correct answer)
Participants must re-consent for every data access
All PHI must be de-identified before any research use
Researchers may access all medical records for any participant

Correct answer: Protected health information should be limited to the minimum needed to accomplish the research purpose

The HIPAA minimum necessary standard requires that access to PHI in research be limited to only what is required to accomplish the specific research purpose.

Question 73: What is the primary purpose of a sponsor's audit of a clinical trial site?

To interview participants about their experience
To independently verify that GCP and protocol requirements are being followed (Correct answer)
To determine whether additional funding is needed
To replace the routine monitoring visit

Correct answer: To independently verify that GCP and protocol requirements are being followed

Sponsor audits are independent evaluations that verify site compliance with GCP, the protocol, and applicable regulations, separate from routine monitoring.

Question 74: What key factor distinguishes a 'Serious Adverse Event' (SAE) from a non-serious adverse event according to ICH GCP guidelines?

The frequency of the event's occurrence within the study population.
The certainty of the event's relationship to the investigational product.
The severity grade of the event (e.g., mild, moderate, severe).
The outcome or consequence of the event meeting specific criteria. (Correct answer)

Correct answer: The outcome or consequence of the event meeting specific criteria.

An SAE is defined by its outcome. According to ICH E6 and FDA definitions, an event is serious if it results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment. Severity is a separate scale and does not automatically make an AE serious. Relatedness and frequency are important for overall safety assessment but do not define 'seriousness'.

Question 75: When should a US clinical trial site register its study on ClinicalTrials.gov?

Only after the study is completed
When the sponsor requests it
Before enrollment of the first participant, as required by FDAAA 801 (Correct answer)
Within 30 days of IRB approval

Correct answer: Before enrollment of the first participant, as required by FDAAA 801

FDAAA 801 requires applicable clinical trials to be registered on ClinicalTrials.gov no later than 21 days after enrolling the first participant, but best practice is prior to first enrollment.

Question 76: Under the Common Rule, which of the following studies qualifies for exemption from full IRB review?

A survey study of adults involving no sensitive topics and no identifiable information (Correct answer)
An observational study of pregnant women with blood draws
A gene therapy study in healthy volunteers
A phase II drug trial in cancer patients

Correct answer: A survey study of adults involving no sensitive topics and no identifiable information

Under 45 CFR 46.104(d)(2), surveys/interviews of adults that do not involve sensitive topics or identifiable information may qualify for exemption from full IRB review.

Question 77: The DSMB has prematurely terminated a trial evaluating an investigational pain medication hat is taken one caplet orally b.i.d. for chronic hip pain. Subject are allowed to take one extra caplet per day. Subjects receive a sufficient quantity of IP for 14 days plus two additional doses. Which of the following represents a drug accountability issue?

Subject A returns 24 pills after 10 days on trial
Subject C returns 29 pills after 5 days on the trial
Subject D returns 42 pills after 1 day on the trial
Subject B returns 12 pills after 8 days on the trial (Correct answer)

Correct answer: Subject B returns 12 pills after 8 days on the trial

The subject was instructed to take 8 tablets per day (2 tablets * 4 times/day). By the morning of day 9, they had completed 8 full days of dosing, meaning they should have taken 8 * 8 = 64 tablets. They were issued 120 tablets and returned 88, indicating they took 120 - 88 = 32 tablets. Compliance is calculated as (Actual tablets taken / Expected tablets taken) * 100 = (32 / 64) * 100 = 50%.

Question 78: If a sponsor places a study on clinical hold, what must the site immediately do?

Transfer all participants to an alternative study
Archive all records and terminate IRB approval
Continue enrollment until official written notice is received
Stop all study-related interventions and enrollment as directed (Correct answer)

Correct answer: Stop all study-related interventions and enrollment as directed

A clinical hold requires the site to immediately suspend enrollment and interventions as directed by the sponsor pending FDA resolution of the safety concern.

Question 79: Which regulatory body must IND sponsors notify when serious or unexpected protocol deviations occur in the United States?

WHO (World Health Organization)
NIH (National Institutes of Health)
FDA (Food and Drug Administration) (Correct answer)
ICH (International Council for Harmonisation)

Correct answer: FDA (Food and Drug Administration)

Under 21 CFR Part 312, IND sponsors must report significant protocol deviations and safety issues to the FDA.

Question 80: In a double-blind study, a participant experiences a severe adverse event requiring hospitalization. The emergency room physician believes knowing the treatment assignment is critical for patient management. What is the CRC's most appropriate initial action?

Instruct the physician to treat the symptoms without unblinding to protect the integrity of the study.
Contact the Principal Investigator (PI) immediately and follow the protocol-specific procedure for emergency unblinding. (Correct answer)
Immediately access the unblinding envelope and inform the physician of the treatment assignment.
Tell the physician to call the sponsor's general hotline to request the unblinding information directly.

Correct answer: Contact the Principal Investigator (PI) immediately and follow the protocol-specific procedure for emergency unblinding.

Patient safety is paramount, but unblinding must follow a pre-defined process to protect study integrity as much as possible. The protocol will specify the exact steps for emergency unblinding. The CRC's role is to immediately involve the PI, who is medically responsible, and initiate the formal procedure. The PI must be able to unblind a participant independently in a medical emergency without delay or requiring permission from the sponsor.

Question 81: A study participant in a clinical trial for a new hypertension medication reports a persistent, severe headache. The headache is listed in the Investigator's Brochure as a possible side effect. According to ICH GCP guidelines, how should this event be classified?

As a protocol deviation since the event was expected.
As a Serious Adverse Event (SAE) because it is severe.
As an Adverse Event (AE). (Correct answer)
As an Unanticipated Problem Involving Risks to Subjects or Others (UPIRSO).

Correct answer: As an Adverse Event (AE).

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Since the headache is a medical occurrence during the trial, it is an AE. It is not an SAE because it does not meet the criteria for seriousness (e.g., life-threatening, requiring hospitalization). Severity (severe headache) is not the same as seriousness. It is not a UPIRSO because the event was anticipated (listed in the Investigator's Brochure). It is not a protocol deviation, but rather a clinical event to be documented and reported per protocol.

Question 82: What is one way a Clinical Research Coordinator can increase their salary potential?

Pursuing further education
All of the above (Correct answer)
Gaining additional
Obtaining advanced certifications

Correct answer: All of the above

Increasing salary potential for a Clinical Research Coordinator involves a multi-faceted approach. Gaining additional experience, especially in complex trials or leadership roles, directly enhances market value. Obtaining advanced certifications, such as the CCRC, demonstrates specialized knowledge and commitment, while pursuing further education like a Master's degree can open doors to higher-level positions and increased earning capacity.

Question 83: A Clinical Research Coordinator (CRC) is notified that a study participant has been hospitalized due to a suspected reaction to the investigational drug. According to FDA regulations for IND trials, what is the maximum timeframe for the sponsor to report this unexpected fatal or life-threatening suspected adverse reaction to the FDA?

As soon as possible, but no later than 7 calendar days. (Correct answer)
No later than 15 calendar days.
Within 10 working days.
Within 24 hours of the site becoming aware of the event.

Correct answer: As soon as possible, but no later than 7 calendar days.

FDA regulation 21 CFR 312.32(c)(2) requires sponsors to notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 calendar days after the sponsor's initial receipt of the information. The 15-day timeframe applies to other serious and unexpected suspected adverse reactions.

Question 84: A CRA is conducting a close-out visit at a site to review the regulatory documents. The CRC has prepared the following documents to be filed and/or sent to the sponsor: treatment decoding documentation code list, documentation of IP destruction and final report to the IRB/IEC. Which of the following actions should the CRC perform?

Send the treatment decoding documentation to the sponsor (Correct answer)
Send copies of the IP destruction forms to the sponsor. (Correct answer)
Remove the subject identification code list from the material to be sent to the sponsor. (Correct answer)
Remove the drug accountability log from the material to be sent to the sponsor

Correct answer: Send the treatment decoding documentation to the sponsor

During a close-out visit, the CRC must ensure all required documents are properly filed and submitted according to sponsor and regulatory guidelines. The treatment decoding documentation (e.g., randomization code list) is crucial for the sponsor to unblind the study data and is typically sent to them. Subject identification code lists should be retained at the site to protect subject privacy, and drug accountability logs are usually retained by the site for audit purposes, with copies of destruction forms sent to the sponsor.

Question 85: A subject is issued 120 tablets and is instructed to take 2 tablets 4 times a day. He returns 88 tablets on the morning of day 9 fasting for laboratory tests. What percent compliant is he?

25%
20%
30%
50% (Correct answer)

Correct answer: 50%

If 92 bottles are available for the CRC to return from an initial supply of 100 bottles, it means that 8 bottles were ultimately not returned (100 - 92 = 8). This implies that despite 26 subjects being enrolled and each receiving two bottles (52 bottles dispensed), only 8 bottles were consumed or otherwise unaccounted for, with the remaining dispensed bottles being returned unused.

Question 86: A participant returns a partially used bottle of an oral investigational drug at a routine study visit. According to good clinical practice, what is the CRC's primary responsibility regarding the returned product?

Accurately count the returned units, document the quantity on the accountability log, and store it securely per sponsor/protocol instructions. (Correct answer)
Offer the unused product to another participant who may have lost their supply to prevent waste.
Immediately dispose of the unused product in a standard biohazard container.
Instruct the participant to take the remaining product home for proper disposal.

Correct answer: Accurately count the returned units, document the quantity on the accountability log, and store it securely per sponsor/protocol instructions.

The site must maintain complete accountability for the investigational product from receipt to final disposition. This includes documenting the exact quantity of product returned by the participant and storing it securely. This process is crucial for assessing compliance and ensuring a complete reconciliation of all IP units at the end of the study, which are then either returned to the sponsor or destroyed according to the sponsor's specific written instructions.

Question 87: According to ICH GCP E6 (R2), which document is specifically maintained at the trial site to record all individuals who have been delegated significant trial-related duties by the Principal Investigator (PI)?

Form FDA 1572
The protocol signature page
Financial Disclosure Form
Delegation of Authority (DoA) Log (Correct answer)

Correct answer: Delegation of Authority (DoA) Log

The Delegation of Authority (DoA) Log, also known as the Site Signature and Responsibility Log, is the essential document that prospectively captures all study staff members, their assigned roles, start/end dates, and signatures. While the Form FDA 1572 lists the PI and sub-investigators, it does not detail the specific delegated tasks for the entire team, such as coordinators, pharmacists, or research nurses.

Question 88: During a sponsor monitoring visit, the Clinical Research Associate (CRA) requests access to source documents. What is the coordinator's obligation?

Provide access only if the participant consents again
Allow access only with IRB approval for each visit
Deny access to protect participant privacy entirely
Provide access per the consent form and applicable regulations (Correct answer)

Correct answer: Provide access per the consent form and applicable regulations

Source document access for monitors is typically authorized in the informed consent form and is required under GCP to verify data integrity.

Question 89: A study participant completed a required blood draw 5 days outside the protocol-specified visit window. This is an example of:

A regulatory violation requiring FDA notification
An unanticipated problem requiring immediate IRB reporting
A protocol deviation (Correct answer)
A serious adverse event

Correct answer: A protocol deviation

Missing a required assessment window is a common type of protocol deviation that must be documented in the site's deviation log.

Question 90: What are some common career advancements for Clinical Research Coordinators?

Clinical Trial Manager
All of the above (Correct answer)
Clinical Research Associate (CRA)
Regulatory Affairs Specialist

Correct answer: All of the above

Clinical Research Coordinators gain valuable experience in trial management, regulatory compliance, and patient interaction, which are foundational for various advanced roles. Moving to a Clinical Research Associate (CRA) involves monitoring multiple sites, while a Clinical Trial Manager oversees entire studies. Specializing in Regulatory Affairs also leverages a CRC's understanding of compliance, making all these viable career advancements.

Question 91: In a clinical trial, a p-value of <0.05 is typically interpreted as:

The observed result is statistically significant, and the null hypothesis is rejected. (Correct answer)
The result is clinically significant and proves the new treatment is superior.
There is a greater than 95% chance that the alternative hypothesis is true.
The probability that the null hypothesis is true is less than 5%.

Correct answer: The observed result is statistically significant, and the null hypothesis is rejected.

A p-value represents the probability of observing the study results (or more extreme results) if the null hypothesis were true. A p-value of less than 0.05 is a conventional threshold used to declare a result 'statistically significant,' meaning the observed difference is unlikely to be due to chance alone, leading to the rejection of the null hypothesis. It does not, however, indicate the size or clinical importance of the effect.

Question 92: A sponsor issues a Safety Letter describing a new serious risk identified in another study. What is the coordinator's required action?

Submit the safety information to the IRB promptly (Correct answer)
Report directly to the FDA on behalf of the sponsor
Update the protocol without IRB review
File it and wait for the next monitoring visit

Correct answer: Submit the safety information to the IRB promptly

New safety information received from the sponsor must be forwarded to the IRB in a timely manner so the IRB can assess whether consent forms or protocols need updating.

Question 93: When a sponsor sends a protocol amendment that changes inclusion/exclusion criteria, what must the site coordinator do FIRST?

Implement the change immediately to protect participants
Enroll the next eligible participant using new criteria
Submit the amendment to the IRB for approval before implementing (Correct answer)
Notify the FDA within 24 hours

Correct answer: Submit the amendment to the IRB for approval before implementing

Protocol amendments that affect participant safety or study conduct must receive IRB approval before implementation at the site.

Question 94: A small biotech company is investigating the anti-tumoral potential of scorpion toxin in high grade recurrent brain tumors. After animal trials have been completed, the first trial in humans would MOST likely involve:

healthy volunteers
placebo control
pharmacokinetic analysis (Correct answer)
dose escalation (Correct answer)

Correct answer: pharmacokinetic analysis

To convert weight from pounds (lb) to kilograms (kg), you divide the weight in pounds by the conversion factor of approximately 2.20462. Therefore, 123 lb / 2.20462 lb/kg ≈ 55.79 kg, which rounds to 56 kg.

Question 95: A CRC is preparing to dispense an investigational drug to a study participant for the first time. Which of the following is a critical prerequisite before any drug can be dispensed to that specific participant?

Updating the electronic Case Report Form (eCRF) with the anticipated dispensing date.
Verifying that the site has received payment from the sponsor for the participant's screening visit.
Confirming that a valid, signed informed consent form for the participant is on file and the PI has authorized the prescription/order. (Correct answer)
Ensuring the participant has scheduled their next three study visits.

Correct answer: Confirming that a valid, signed informed consent form for the participant is on file and the PI has authorized the prescription/order.

Before any study procedures, including the dispensing of an investigational drug, can occur, the participant must have voluntarily given informed consent, which must be documented via a signed and dated consent form. Furthermore, the dispensing of the drug, like any prescription, must be done upon the order of the Principal Investigator or another authorized prescriber as delegated. The pharmacy or person dispensing must verify these elements are in place before releasing the IP.

Question 96: What is the significance of the Tuskegee Syphilis Study to modern US research ethics?

It led directly to the creation of the FDA
It was the first US clinical trial to use a placebo control
It established the requirement for IRB approval of all research
It exposed exploitation of a vulnerable population and directly prompted the National Research Act and Belmont Report (Correct answer)

Correct answer: It exposed exploitation of a vulnerable population and directly prompted the National Research Act and Belmont Report

The Tuskegee study's ethical failures — withholding known treatment from Black men — led to the 1974 National Research Act and the Belmont Report that governs US research ethics today.

Question 97: Which group is specifically designated as a 'vulnerable population' requiring additional protections under US federal regulations (45 CFR 46 Subparts B–D)?

Prisoners, pregnant women/fetuses, and children (Correct answer)
Participants with private health insurance
Healthcare workers enrolled in occupational studies
Participants over age 65

Correct answer: Prisoners, pregnant women/fetuses, and children

45 CFR 46 Subparts B (pregnant women/fetuses), C (prisoners), and D (children) provide additional protections for these groups due to their potential vulnerability to coercion or compromised autonomy.

Question 98: Research misconduct in the US is formally defined under federal policy to include which of the following?

Disagreements among co-investigators about study design
Fabrication, falsification, and plagiarism in proposing, performing, or reviewing research (Correct answer)
Publishing negative study results
Honest errors in data interpretation

Correct answer: Fabrication, falsification, and plagiarism in proposing, performing, or reviewing research

The US federal definition of research misconduct (42 CFR Part 93) covers fabrication, falsification, and plagiarism; it excludes honest error and differences of opinion.

Question 99: Which section of the ICH GCP E6(R2) guideline specifically addresses clinical trial protocol content and protocol amendments?

Section 8 — Essential Documents for the Conduct of a Clinical Trial
Section 3 — Institutional Review Board / Independent Ethics Committee
Section 2 — Principles of ICH GCP
Section 6 — Clinical Trial Protocol and Protocol Amendment(s) (Correct answer)

Correct answer: Section 6 — Clinical Trial Protocol and Protocol Amendment(s)

ICH GCP E6(R2) Section 6 covers the required content and regulatory requirements for the clinical trial protocol and its amendments.

Question 100: Which of the following BEST distinguishes a protocol violation from a protocol deviation?

Violations significantly affect participant safety or data integrity; deviations are minor departures (Correct answer)
Violations require sponsor approval; deviations require IRB approval
Violations are always intentional; deviations are always accidental
Violations are reported to the FDA; deviations are only reported internally

Correct answer: Violations significantly affect participant safety or data integrity; deviations are minor departures

Protocol violations are deviations that significantly affect participant rights, safety, welfare, or data integrity, whereas deviations are typically minor departures.

Question 101: A clinical research study that was initially approved by a full IRB committee is approaching its one-year approval anniversary. What is the primary purpose of the IRB's continuing review for this ongoing study?

To reassess the risk-benefit ratio and ensure the continued protection of the rights and welfare of research participants. (Correct answer)
To renegotiate the site's budget based on the complexity and number of participants enrolled.
To verify the accuracy of the data collected and ensure it aligns with the study's primary objectives.
To provide a formal summary of enrollment statistics to the study sponsor and regulatory authorities.

Correct answer: To reassess the risk-benefit ratio and ensure the continued protection of the rights and welfare of research participants.

The fundamental purpose of IRB continuing review is to ensure that the study, as it is actually being conducted, continues to meet the ethical standards and regulatory criteria for approval. This involves re-evaluating the risks and benefits based on study progress, any new information, and ensuring that protections for participants remain adequate.

Question 102: Which of the following represents an example of undue inducement in clinical trial recruitment?

Describing study procedures clearly in the consent form
Offering compensation so large that it impairs participants' ability to assess risks objectively (Correct answer)
Reimbursing participants for parking and travel expenses
Enrolling participants who are also the PI's patients

Correct answer: Offering compensation so large that it impairs participants' ability to assess risks objectively

Undue inducement occurs when compensation is so large that it compromises a prospective participant's ability to make a free, rational decision about study risks.

Question 103: Which of the following is the most appropriate and GCP-compliant method for a Principal Investigator (PI) to document the assignment of study-related tasks to qualified site staff?

A single note-to-file written by the CRC after the study has been completed, summarizing who did what.
A signed and dated Delegation of Authority (DoA) Log specifying tasks, start/end dates, and staff qualifications. (Correct answer)
An email from the PI to the sponsor listing the names of the research team members.
A verbal agreement made with each staff member during a team meeting.

Correct answer: A signed and dated Delegation of Authority (DoA) Log specifying tasks, start/end dates, and staff qualifications.

The Delegation of Authority (DoA) Log is the standard, essential document used to formally record which study-specific duties have been assigned by the PI to specific, qualified individuals on the team. This log provides a contemporaneous record that is crucial for regulatory compliance and is often reviewed during monitoring visits and audits. Verbal agreements, informal emails, or retrospective notes are not sufficient to meet GCP standards for documenting delegation.

Question 104: During a site close-out visit, the Clinical Research Coordinator (CRC) and the monitor are reconciling the investigational product (IP) accountability records. What is the primary purpose of this reconciliation?

To determine the final payment owed to the site for dispensing the IP.
To finalize the recruitment statistics for the study based on the number of participants who received IP.
To ensure all IP units were correctly dispensed, returned to the sponsor, or appropriately destroyed, accounting for every unit received. (Correct answer)
To identify which participants were most compliant with the treatment regimen for the final study report.

Correct answer: To ensure all IP units were correctly dispensed, returned to the sponsor, or appropriately destroyed, accounting for every unit received.

IP accountability is a critical GCP requirement to ensure the product was used only as specified in the protocol and to prevent diversion. The reconciliation process at the close-out visit provides a final accounting of every IP unit received at the site, confirming it was either dispensed to a participant, returned to the sponsor, or destroyed according to procedure. While dispensing data may inform other analyses, the primary purpose of this specific activity is regulatory compliance and product control.

Question 105: If the patient's weight is 123 lb, what is the weight in kg?

45
65
56 (Correct answer)
54

Correct answer: 56

The regulatory binder must contain all essential trial documents. When a protocol is amended, the 'amended protocol' itself is required to detail the changes. Additionally, an 'IRB/IEC letter of approval for the amended protocol' is crucial to document ethical oversight. The 'Investigator's Brochure' (IB), providing comprehensive information about the investigational product, is a fundamental document that must always be included in the binder.

Question 106: Which of the following industries employs the highest number of Clinical Research Coordinators?

Academic Research Institutions
Non-Profit Organizations
Pharmaceutical Companies (Correct answer)
Government Agencies

Correct answer: Pharmaceutical Companies

Pharmaceutical companies are the primary sponsors of clinical trials, investing heavily in the research and development of new drugs and therapies. This extensive involvement creates a high demand for Clinical Research Coordinators (CRCs) to manage the day-to-day operations of these trials, ensuring compliance and data integrity. While other institutions also employ CRCs, the sheer volume of drug development makes pharmaceutical companies the largest employer.

Question 107: In which setting are Clinical Research Coordinators likely to manage patient recruitment and retention?

Biotechnology Firms
Academic Medical Centers (Correct answer)
Government Agencies
Pharmaceutical Companies

Correct answer: Academic Medical Centers

Academic Medical Centers (AMCs) are often sites for investigator-initiated trials and early-phase studies, where patient recruitment and retention are particularly challenging and critical. CRCs in these settings work closely with principal investigators and patients, directly managing the complex processes of identifying eligible participants, enrolling them, and ensuring their continued engagement throughout the study. While other entities conduct trials, AMCs frequently have a direct, hands-on role in patient-facing aspects.

Question 108: A study participant who is enrolled in a clinical trial later loses decision-making capacity. What is the ethical obligation of the research team?

Continue the study as originally consented without modification
Consult the sponsor for permission to continue
Automatically withdraw the participant from all study procedures
Obtain consent from a legally authorized representative (LAR) to continue participation (Correct answer)

Correct answer: Obtain consent from a legally authorized representative (LAR) to continue participation

When a participant loses capacity, ongoing research participation requires consent from a legally authorized representative unless the IRB has approved a waiver.

Question 109: To ensure an efficient interim monitoring visit where the primary purpose is source data verification (SDV), which of the following is the most important preparatory task for the CRC?

Wait for the CRA to arrive to ask what data needs to be entered into the electronic data capture (EDC) system.
Ensure all source documents are complete, organized, and readily accessible for the subjects being monitored. (Correct answer)
Schedule all upcoming participant visits for the day the Clinical Research Associate (CRA) is on-site.
Prepare a detailed summary of recruitment and retention challenges for the sponsor.

Correct answer: Ensure all source documents are complete, organized, and readily accessible for the subjects being monitored.

The core function of Source Data Verification (SDV) is the comparison of data entered into the EDC system against the original source documents to ensure accuracy and completeness. The most crucial step for the CRC to facilitate this process is to have all necessary source documents—such as medical records, lab reports, and participant diaries—organized and available for the monitor's review. This preparation is key to a productive and efficient monitoring visit.

Question 110: The protocol and protocol summary have been submitted to a central IRB/IEC for review/approval by the CRO prior to the investigator's meeting. <br> Following the meeting, the entry criteria are altered to facilitate the recruitment and retention of eligible subjects. Prior to trial start-up, the regulatory binder must include:

an IRB/IEC letter of approval for the amended protocol (Correct answer)
the amended protocol (Correct answer)
an IRB/IEC site valuation form
the Investigator's Brochure (Correct answer)

Correct answer: an IRB/IEC letter of approval for the amended protocol

In a purely competitive market, products are undifferentiated, and firms are price takers. Strategies like lean manufacturing, process reengineering, and supply chain management focus on cost efficiency. Developing a brand name aims to differentiate a product and build customer loyalty, which is a strategy for markets with some degree of monopolistic competition, not a purely competitive market where products are homogeneous.

Question 111: A sponsor monitor identifies a pattern of protocol deviations at your site. What regulatory consequence could the site face?

Automatic participant compensation
Placement on a clinical hold or site termination (Correct answer)
Transfer of site data to another investigator
Mandatory IRB re-approval of all prior participants

Correct answer: Placement on a clinical hold or site termination

Repeated or serious protocol deviations can lead the sponsor or FDA to place the site on clinical hold or terminate its participation to protect trial integrity.

Question 112: Which of the following are responsibilities of an IDMC/DSMB

assess the progress of a trial (Correct answer)
assess the financial aspects of a trial
recommend stopping a trial (Correct answer)
recommend initiating a trial

Correct answer: assess the progress of a trial

An Independent Data Monitoring Committee (IDMC) or Data Safety Monitoring Board (DSMB) is an independent group of experts that periodically reviews accumulating data from an ongoing clinical trial. Their primary responsibilities include assessing the safety and efficacy data, monitoring the overall progress of the trial, and making recommendations to the sponsor regarding the continuation, modification, or termination of the study. They ensure the ethical conduct and scientific integrity of the trial.

Question 113: A PI has an enrollment goal of 24 subjects. Ten potential subjects are seen each week. Twenty percent of the potential subjects will not be interested in participating. Fifty percent of the subjects who are interested will fail to meet one or more inclusion/exclusion criteria. How long will it take the CRC to fulfill enrollment?

6 weeks (Correct answer)
5 weeks
7 weeks
8 weeks

Correct answer: 6 weeks

To calculate the time needed, first determine the number of eligible subjects per week. Out of 10 potential subjects, 20% are not interested (10 * 0.20 = 2), leaving 8 interested subjects. Of these 8, 50% fail screening (8 * 0.50 = 4), meaning 4 eligible subjects are enrolled per week. To reach an enrollment goal of 24 subjects, it will take 24 subjects / 4 subjects/week = 6 weeks.

Question 114: Which document is primarily used at a clinical research site to track and manage protocol deviations?

Site Master File
Investigator's Brochure
Protocol Deviation Log (Correct answer)
Case Report Form (CRF)

Correct answer: Protocol Deviation Log

A Protocol Deviation Log is maintained at the site to systematically track, categorize, and manage all deviations from the approved protocol.

Question 115: How long must US clinical trial records generally be retained after study completion under FDA regulations?

10 years
5 years
2 years
At least 2 years after the last marketing application approval or the study is discontinued (Correct answer)

Correct answer: At least 2 years after the last marketing application approval or the study is discontinued

Under 21 CFR 312.62, investigators must retain records for at least 2 years after the last marketing application approval, or if no application is filed, 2 years after study discontinuation.

Question 116: A sponsor has successfully completed a Phase I trial for a new oncology drug, establishing its initial safety profile and identifying a maximum tolerated dose in healthy volunteers. What is the primary objective of the subsequent Phase II clinical trial?

To confirm the drug's efficacy and safety in a large, diverse patient population to support a New Drug Application (NDA).
To evaluate the drug's effectiveness for a specific cancer type in a well-defined patient group and to further assess its short-term safety and side effects. (Correct answer)
To determine the drug's metabolism, pharmacokinetic properties, and major toxicities for the first time in human subjects.
To gather post-marketing data on the drug's long-term risks, benefits, and optimal use in the general patient population.

Correct answer: To evaluate the drug's effectiveness for a specific cancer type in a well-defined patient group and to further assess its short-term safety and side effects.

Phase II trials are the first to test a new drug's efficacy in patients with the target disease or condition. After initial safety is established in Phase I, the goal of Phase II is to see if the drug works for its intended purpose in a limited patient group and to continue monitoring safety to determine a proper dose for larger studies.

Question 117: In the hierarchy of evidence for clinical research, which of the following study designs provides the most robust and reliable evidence for the efficacy of a new intervention?

Systematic review or meta-analysis of randomized controlled trials (Correct answer)
Cohort study
Case-control study
Expert opinion

Correct answer: Systematic review or meta-analysis of randomized controlled trials

A systematic review or meta-analysis sits at the pinnacle of the evidence hierarchy. It synthesizes the results of multiple high-quality randomized controlled trials (RCTs), providing a more comprehensive and statistically powerful conclusion than any single study. While RCTs themselves are strong, a meta-analysis combines their data, increasing the overall sample size and reducing the likelihood of random error, thus offering the highest level of evidence.

Question 118: A new investigational product (IP) shipment is scheduled to arrive. The protocol specifies the IP must be stored between 2-8°C. The CRC notes that the temperature monitoring device for the site's drug storage refrigerator has not been calibrated in over a year. What is the most critical immediate action for the CRC?

Notify the sponsor/CRO and arrange for an immediate calibration of the device before accepting the IP shipment. (Correct answer)
Relocate the new IP shipment to a standard breakroom refrigerator temporarily.
Proceed with dispensing IP to participants as scheduled from existing stock.
Accept the shipment and begin recording the temperatures manually every hour with a standard thermometer.

Correct answer: Notify the sponsor/CRO and arrange for an immediate calibration of the device before accepting the IP shipment.

Maintaining the integrity of the investigational product is paramount for patient safety and data validity. GCP guidelines require that storage conditions are acceptable and equipment is properly maintained. An uncalibrated temperature monitoring device means there is no reliable record of the storage temperature. The CRC must ensure equipment is calibrated *before* using it to store the new IP shipment and should communicate this issue to the sponsor immediately.

Question 119: Protocol deviations that affect participant safety must typically be reported to the IRB within:

The timeframe specified by the IRB's own policies, often within 5–10 business days (Correct answer)
Only at the annual continuing review submission
6 months of the occurrence
1 year of the occurrence date

Correct answer: The timeframe specified by the IRB's own policies, often within 5–10 business days

IRBs typically require prompt reporting of deviations affecting safety within their specified timeframes, which are often measured in business days rather than months.

Question 120: According to federal regulations (45 CFR 46 and 21 CFR 50), the informed consent process must minimize the possibility of coercion or undue influence. Which scenario best exemplifies undue influence?

An investigator offers an excessively large monetary payment to a financially vulnerable individual to encourage enrollment in a high-risk study. (Correct answer)
An investigator tells their own patient that their access to standard medical care will be limited if they do not enroll in the clinical trial.
A CRC offers a potential participant an IRB-approved compensation of $50 for each study visit to cover time and travel.
A CRC provides a potential participant with a thorough explanation of the study in a private, quiet room.

Correct answer: An investigator offers an excessively large monetary payment to a financially vulnerable individual to encourage enrollment in a high-risk study.

Undue influence occurs when an excessive or inappropriate reward is offered to obtain compliance, which can compromise a person's judgment. While compensating participants is acceptable, an amount that is disproportionate to the study's demands, especially when offered to a vulnerable population, is considered undue influence. Telling a patient their care depends on participation is an example of coercion (a threat of harm).

Question 121: A Clinical Research Coordinator (CRC) receives a shipment of investigational product that must be stored between 2-8°C. The temperature monitoring device packed with the shipment indicates a temperature of 10°C for the last four hours of transit. What is the most appropriate immediate action for the CRC?

Quarantine the shipment, document the temperature excursion, and notify the sponsor for instructions. (Correct answer)
Dispense the drug to participants immediately to avoid waste.
Place the drug in the proper refrigerator and use it once it has cooled to the correct temperature range.
Return the shipment directly to the sponsor without notifying anyone at the site.

Correct answer: Quarantine the shipment, document the temperature excursion, and notify the sponsor for instructions.

The integrity of the investigational product is paramount. A temperature excursion may affect the product's stability, safety, and efficacy. The correct procedure is to secure the product to prevent its use (quarantine), document the event thoroughly, and immediately contact the sponsor for guidance. The sponsor must assess the excursion data and determine if the product is still viable or must be destroyed or returned.

Question 122: Which of the following is a primary responsibility of the CRC during the informed consent process?

Assessing the potential participant's understanding of the study information provided. (Correct answer)
Ensuring the investigator has signed the ICF before the participant.
Determining the participant's medical eligibility for the study.
Deciding on the compensation amount for study participation.

Correct answer: Assessing the potential participant's understanding of the study information provided.

While the CRC has many roles, a key ethical and regulatory responsibility is to ensure the participant truly understands the study. This involves more than just presenting information; it includes asking open-ended questions, using teach-back methods, and assessing both verbal and non-verbal cues to confirm comprehension before the participant signs the form.

Question 123: Twenty-six subjects were enrolled in a pneumonia trial. The site received 100 bottles of IP. Each subject received two bottles. How many bottles are available for the CRC to return to the sponsor at the end of the trial?

95
90
92 (Correct answer)
82

Correct answer: 92

A double-blind trial is characterized by neither the subjects nor the investigators (clinical team) knowing which treatment is being administered. In this scenario, the pharmacist and sponsor know the IP identity, but the pharmacist has no direct contact with the subject or clinical team, ensuring that both the subject and the clinical staff interacting with them are unaware of the treatment assignment.

Question 124: What constitutes a conflict of interest (COI) for a clinical investigator in the US?

Receiving salary support from a federal grant
Holding a medical license while conducting research
Having a significant financial interest in the sponsor or study outcome (Correct answer)
Enrolling participants from their own patient population

Correct answer: Having a significant financial interest in the sponsor or study outcome

A COI arises when an investigator's significant financial interest — such as equity, royalties, or consulting fees — could bias study conduct or reporting.

Question 125: A medical device company has developed a novel, implantable deep brain stimulation device for treating severe depression. This type of device is considered a significant risk. Before initiating a clinical trial to evaluate its safety and effectiveness, the sponsor must obtain which of the following from the FDA?

A Premarket Approval (PMA).
A New Drug Application (NDA).
An Investigational Device Exemption (IDE). (Correct answer)
A 510(k) premarket notification clearance.

Correct answer: An Investigational Device Exemption (IDE).

An Investigational Device Exemption (IDE) allows an investigational device that poses a significant risk to be used in a clinical study to collect safety and effectiveness data. A 510(k) and a PMA are applications for marketing a device, not for conducting an investigational trial. An NDA is for drugs, not devices.

CCRC Certification Exam

The Certified Clinical Research Coordinator (CCRC) exam is administered by the Association of Clinical Research Professionals (ACRP). It validates the knowledge and skills required of clinical research coordinators who manage day-to-day operations of clinical trials at investigative sites. The exam covers scientific concepts, ethical standards, regulatory requirements, informed consent, participant safety, data management, GCP compliance, IRB roles, and investigational product management. Candidates must meet eligibility requirements including a combination of education and clinical research experience.

125

Questions

180 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds

These practice questions were written with AI tools. They are not real exam questions. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

acrpnet.org — Eligibility, fees, exam format, score release, time limit, score validity, renewal, retake fee, retake policy, test delivery · verified Nov 2026